Book a Meeting

Non-Fucosylated Anti-Human CD80 (L104EA29YIg) Therapeutic Antibody (CAT#: BioBet-684ZP) Datasheet

Target
CD80
Isotype
IgG
Description
ADCC-Enhanced anti-CD80 (L104EA29YIg) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Immune System Diseases
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD80 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD80
Full Name
CD80 molecule
Background
The protein encoded by this gene is a membrane receptor that is activated by the binding of CD28 or CTLA-4. The activated protein induces T-cell proliferation and cytokine production. This protein can act as a receptor for adenovirus subgroup B and may play a role in lupus neuropathy.
Alternative Names
CD80; CD80 molecule; B7; BB1; B7-1; B7.1; LAB7; CD28LG; CD28LG1; T-lymphocyte activation antigen CD80; activation B7-1 antigen; costimulatory factor CD80; CTLA-4 counter-receptor B7.1; B-lymphocyte activation antigen B7; costimulatory molecule variant IgV-CD80; CD80 antigen (CD28 antigen ligand 1, B7-1 antigen)
Gene ID
941
UniProt ID
Q5ZPR3
Cellular Localization
Membrane
Involvement in Disease
Diseases associated with CD80 include Vaccinia and Focal Segmental Glomerulosclerosis.
Related Pathways
Its related pathways are Nur77 Signaling in T-Cell and RET signaling. Gene Ontology (GO) annotations related to this gene include coreceptor activity.
Function
Participate in the costimulatory signals necessary for T lymphocyte activation. CD28 binding induces T cell proliferation and cytokine production, while binding to CTLA-4 has the opposite effect and inhibits T cell activation. (Microbial infection) As a receptor for adenovirus B subgroup.
Field of research
Developmental Biology antibody; Immune System antibody
Post-translational modifications
1.Glycosylation at Asn53, Asn89, Asn98, Asn186, Asn207, Asn211, Asn226, and Asn232 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
L104EA29YIg
Host
Human
Species Reactivity
Human
Description
The binding of L104EA29YIg to CD86 or CD80 can be used to treat immune system diseases such as graft rejection following organ transplant.
Indication
Immune System Diseases

Immune System Diseases

Related Products

BetterBet™ Anti-CD80 Recycling Antibody (CAT#: AES-0622-ZP133)
BetterBet™ Anti-CD80 FcγRIIB Binding Enhanced Antibody (CAT#: AES-0622-ZP461)
Non-fucosylated Anti-Human CD80 (Galiximab) Therapeutic Antibody (CAT#: BioBet-165ZP)
BetterBet™ Anti-CD80 Half-Life Extended Antibody (CAT#: AES-0622-ZP1117)
BetterBet™ Anti-CD80 On-Target Antibody (CAT#: AES-0622-ZP789)
Highly Galactosylated Anti-CD80 (Galiximab) Antibody (CAT#: BioBet-GA-165ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.